Bei Jing Shang Bao·2025-08-19 12:13Group 1 - The company plans to acquire the remaining 7% equity of its subsidiary Guangzhou Nuo Cheng Jian Hua Pharmaceutical Technology Co., Ltd. for no more than 476 million yuan, using its own funds [1] - Upon completion of the acquisition, the company will hold 100% of the equity in Guangzhou Nuo Cheng Jian Hua, enhancing control over the subsidiary and improving operational and decision-making efficiency [1] - The acquisition aims to reduce management costs and risks, optimize resource allocation, and support the company's strategic development goals [1] Group 2 - In the first half of 2025, the company reported revenue of approximately 731 million yuan, representing a year-on-year increase of 74.26% [1] - The revenue growth is primarily attributed to the continued sales increase of the core product, Aobutini (brand name: Yinuokai), and an upfront payment received from a licensing agreement with Prolium [1] - The company's losses narrowed significantly by 86.7% year-on-year, reducing to 36 million yuan, due to increased revenue and improved cost efficiency [1]